N-of-1 Personalized Therapy for CMT2S: From Preclinical Models to First-in-Human Dosing by Anthony Palmeri | Oct 19, 2026
Using PMP22 Antisense Therapy to Test Molecular Myelin Architecture in CMT1A by Anthony Palmeri | Oct 19, 2026
Inhibiting the Integrated Stress Response to Treat tRNA Synthetase–Associated CMT by Anthony Palmeri | Oct 19, 2026
Development of RTX-117, an eIF2B Activator Targeting the Integrated Stress Response by Anthony Palmeri | Oct 19, 2026
